These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11846325)

  • 1. Changes in biochemical markers of bone turnover in women treated with raloxifene: influence of regression to the mean.
    Chapurlat RD; Blackwell T; Bauer DC; Cummings SR
    Osteoporos Int; 2001 Dec; 12(12):1006-14. PubMed ID: 11846325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
    Hansdóttir H; Franzson L; Prestwood K; Sigurdsson G
    J Am Geriatr Soc; 2004 May; 52(5):779-83. PubMed ID: 15086661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of SERMs on bone health. The evaluation of raloxifene treatment for elderly women with osteoporosis using bone turnover markers].
    Hasegawa M; Ichimura S; Satomi K
    Clin Calcium; 2010 Mar; 20(3):413-20. PubMed ID: 20190372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A; Glover SJ; Eastell R
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.
    Prestwood KM; Gunness M; Muchmore DB; Lu Y; Wong M; Raisz LG
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2197-202. PubMed ID: 10852452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
    D'Amelio P; Muratore M; Tinelli F; Tamone C; Cosentino L; Quarta E; Calcagnile F; Carlo Isaia G
    Int J Tissue React; 2003; 25(2):73-8. PubMed ID: 14518596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G; Kriegman A; Gonçalves J; Kianifard F; Warren M; Simon JA
    Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis.
    Bjarnason NH; Sarkar S; Duong T; Mitlak B; Delmas PD; Christiansen C
    Osteoporos Int; 2001; 12(11):922-30. PubMed ID: 11808544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
    Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
    Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism.
    Rubin MR; Lee KH; McMahon DJ; Silverberg SJ
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1174-8. PubMed ID: 12629102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between changes in biochemical markers of bone turnover and prediction value of fracture risk].
    Cyaki O
    Clin Calcium; 2004 Oct; 14(10):39-46. PubMed ID: 15577130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical markers as predictors of rates of bone loss after menopause.
    Rogers A; Hannon RA; Eastell R
    J Bone Miner Res; 2000 Jul; 15(7):1398-404. PubMed ID: 10893690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A; Hannon R; Eastell R
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.